The KEYNOTE-040 and -048 studies investigating pembrolizumab in advanced HNSCC both used the combined positive score (CPS), which is the number of PD-L1 positive cells including tumor cells, lymphocytes, and macrophages divided by all viable tumor cells and multiplied by 100 [13,51]. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.